Skip to main content

Table 2 Summary of included studies by treatments according to HBeAg status

From: Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials

Treatments included in the network meta-analysis Studies (n) DB RCT (n) Patients (n) Publication years
HBeAg-positive patients
Lamivudine (LAM) 12 9 1925 1998–2015
Adefovir (ADV) 6 3 652 2003–2015
Telbivudine (TBV) 4 3 692 2005–2014
Entecavir (ETV) 9 3 1127 2006–2017
Tenofovir disoproxil fumarate (TDF) 6 4 1065 2008–2017
Tenofovir alafenamide (TAF) 1 1 581 2016
Pegylated interferon (PEG-IFN) 6 2 727 2005–2016
Combination therapies 14 4 1740 2005–2016
Placebo (PLA) 4 3 330 1998–2014
Total 29a 15a 8839 1998–2017
HBeAg-negative patients
Lamivudine (LAM) 9 8 1005 1999–2017
Adefovir (ADV) 3 3 401 2003–2015
Telbivudine (TBV) 2 2 242 2009–2014
Entecavir (ETV) 4 3 470 2006–2017
Tenofovir disoproxil fumarate (TDF) 3 3 544 2008–2016
Tenofovir alafenamide (TAF) 1 1 285 2016
Pegylated interferon (PEG-IFN) 6 2 375 2004–2016
Combination therapies 7 2 525 2004–2016
Placebo (PLA) 4 3 180 1999–2007
Total 19a 13a 4046 1999–2017
  1. HBeAg hepatitis B e antigen, n number, DB RCT double-blind randomized controlled trial
  2. aUnique studies